PANDAS and PANS are debilitating conditions characterised by distressing symptoms, ranging from rage to signs of obsessive compulsive disorder.
Read More
Australia’s childcare industry is thriving, with revenue expected to reach $17.2 billion by 2028-29, according to market researcher IBISWorld, driven by government support and extended attendance hours in 2023.
Read More
American retail giant Walmart has increased its commitment to the global nutrition company Nutritional Growth Solutions Ltd (ASX: NGS) by awarding NGS an additional 55 stores for the placement of its new Healthy Heights product, Happy Tummies. This brings the total number of stores stocking Happy Tummies to 850, an increase of 55 stores from
Read More
Growing its influence across the resources industry, RemSense Technologies (ASX: REM) has won a new contract from Woodside Energy for its virtual reality technology that produces ‘virtual plants’ that creates a photographic visual twin of a plant.
Read More
For over two years, China has dominated the global semiconductor chip supply, producing about 80% of it, with the US making just about 12%.
Read More
US markets: US markets were lower, with the Dow Jones down -3.5% and S&P500 down -4.9%, as evidence of a resilient labour market reinforced the case for the Fed to keep rates elevated. Long-dated US treasury yields were higher, with the 2-Yr yield at 5.04% and 10-Yr yield at 4.57%, with the Fed Bank of NY’s
Read More
Come 2025, the Agriculture Tech, or AgTech, market is set to be valued at $35.8 billion, more than double 2021’s $16.6 billion. Supply chain management, farming, monitoring—the opportunities for AgTech companies are endless.
Read More
An ever-dynamic sector eager for constant enhancement, the air traffic control software industry is continually adapting to support the growing global aviation sector.
Read More
Security systems company Intelligent Monitoring Group (ASX: IMB) has struck a deal to acquire a new security business through its recently acquired subsidiary ADT Security Limited New Zealand.
Read More
With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers. The definitive sale agreement of its
Read More
